Clinical Trial Update: BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of BG9588, an anti-CD40L antibody, for lupus nephritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Membranoproliferative Glomerulonephritis

Drugs mentioned

• BG9588

Snippet

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Conditions: Glomerulonephritis, Membranoproliferative, Lupus Nephritis | Phase 2 | Status: COMPLETED